Double Medical Technology Inc

Double Medical Technology Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.13, significantly below the industry median of 0.45, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.95, which is above the industry median of 2.1, suggesting strong short-term liquidity. However, the firm's net cash position is negative after subtracting total debt, signaling potential liquidity constraints in the near term.

Profitability metrics show a return on equity (ROE) of 2.48%, which is below the industry median of 5.2%, and a return on assets (ROA) of 1.71%, also below the industry median of 3.8%. These figures suggest that the company is underperforming its peers in terms of asset and equity utilization. Gross profit margin stands at 64.5%, which is in line with the industry median of 63.2%, but the operating margin of 16.3% is below the median of 18.7%, indicating inefficiencies in operating cost control.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The firm's revenue concentration in a single segment is a notable risk factor, as it limits the ability to offset performance shortfalls in one area with gains in another.

Looking ahead, the company is projected to experience a 12.4% year-over-year revenue growth in the current fiscal year, followed by a 9.8% growth in the next fiscal year. This growth trajectory is slightly below the industry median of 14.2% and 11.5%, respectively, indicating a moderate but lagging expansion. The firm's capital expenditure is negative at -142.07 million CNY, suggesting a focus on cost reduction rather than expansion.

Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as the company has not issued additional shares in the past year. The firm's ESG score of 28.89 and a C- grade indicate subpar environmental, social, and governance performance relative to industry peers. The governance pillar score of 62.07 is relatively strong, but the low social pillar score of 13.59 highlights significant social responsibility concerns.

Recent events include a 10-K filing that disclosed ongoing supply chain disruptions and a 2026-04 regulatory update on medical device approvals in China. These events may impact the company's ability to maintain its current growth trajectory.

Double Medical Technology Inc (002901.SZ) has been formally classified within the Healthcare economic sector, specifically under the Healthcare Services & Equipment activity category. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry standards for healthcare providers and equipment manufacturers. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is now rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment suggests that current equity dynamics are favorable for existing shareholders, reducing concerns regarding ownership dilution. In contrast, liquidity risk has been assessed at a medium level. This classification highlights a moderate degree of uncertainty regarding the company’s ability to meet short-term financial obligations or trade volume constraints. While not critical, this medium rating warrants attention to cash flow management and market depth to ensure operational continuity. These updates collectively refine the investment profile of Double Medical Technology by establishing baseline risk parameters and sector alignment. The combination of low dilution risk and medium liquidity risk offers a nuanced view of the company’s financial health, while the healthcare sector classification aids in benchmarking against relevant industry peers. No analyst coverage or index membership data is currently available to further contextualize these findings.

Revenue surged 21.8% year-over-year to CNY 2.6 billion, demonstrating strong top-line growth momentum in the latest fiscal period.

Net income jumped 68.1% to CNY 600 million, significantly outpacing revenue growth and indicating substantial operating leverage.

Free cash flow improved by 247.8% to CNY 426 million, reversing previous deficits and strengthening the liquidity position.

Cash conversion ratio of 1.75 exceeds the cohort median of 0.84, reflecting efficient translation of earnings into cash.

Long-term debt increased sharply to CNY 600 million in FY-2, signaling a significant rise in leverage and financial risk.

The company faces a high credit risk flag, suggesting potential difficulties in meeting financial obligations or securing favorable financing.

Return on equity of 2.5% remains low, suggesting limited efficiency in generating profits from shareholder equity.

Revenue ¥1.53B, +6,9% YoY; Operating income −29,8% YoY.

• ▍Revenue ¥1.53B, +6,9% YoY
• ▍Operating income −29,8% YoY
• ▍Net income −36,3% YoY
• ▍Free cash flow +59,6% YoY
• ▍Net margin 3.8%

Revenue ¥1.43B, −28,1% YoY; Operating income −81,7% YoY.

• ▍Revenue ¥1.43B, −28,1% YoY
• ▍Operating income −81,7% YoY
• ▍Net income −86,2% YoY
• ▍Free cash flow −242,5% YoY
• ▍Net margin 6.5%

Revenue ¥1.99B; Operating income ¥802.9M.

• ▍Revenue ¥1.99B
• ▍Operating income ¥802.9M
• ▍Net margin 33.8%